CCCCC4 Therapeutics, Inc.

$239M

FY 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$21M+10.4% YoY

Gross Profit

$21M100.0% margin

Operating Income

-$35M-165.8% margin

Net Income

-$34M-159.5% margin

EPS (Diluted)

$-0.79

Cash Flow

Operating Cash Flow

$56M

Free Cash Flow

$54M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$118M

Total Liabilities

$230M

Stockholders' Equity

-$112M

Cash & Equivalents

$91M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$21M	$19M	+10.4%
Gross Profit	$21M	-$9M	+331.7%
Operating Income	-$35M	-$16M	-116.3%
Net Income	-$34M	-$16M	-117.0%

CCCC FY 2019 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena